Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDIAG
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
CDIAG is an investigational **co-administration chemotherapy regimen** for relapsed or refractory acute myeloid leukemia. It combines the epigenetic agents chidamide, a histone deacetylase inhibitor, and decitabine, a DNA methyltransferase inhibitor, with low-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor. The regimen was evaluated as a double epigenetic-priming approach in a Phase 2 study sponsored by The First Affiliated Hospital of Soochow University; the published study enrolled 35 patients and reported a complete remission rate of 42.9% and median overall survival of 11.7 months. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.726926/full))
- Other names
- CDIAG regimenchidamide + decitabine + cytarabine + idarubicin + granulocyte colony-stimulating factordouble epigenetic priming regimen
02
Targets
DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNA polymerase familyCSF3R (Granulocyte colony-stimulating factor receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on CDIAG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDIAG.